Acadia Pharmaceuticals Inc. vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 9 compared factors.
Size & Scale
| ACAD | LLY | |
|---|---|---|
| Market Cap | $3.56 billion | $1.05 trillion |
| Revenue (TTM) | $1.14 billion | $79.67 billion |
| Net Income (TTM) | $380.48 million | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| ACAD | LLY | |
|---|---|---|
| P/E Ratio | 9.27 | 39.77 |
| Price / Book | 2.73 | 31.14 |
| Price / Sales | 3.13 | 13.24 |
ACAD leads on 3 of 3 valuation factors.
Profitability
| ACAD | LLY | |
|---|---|---|
| Net Margin | 33.42% | 33.53% |
| Return on Equity | 29.12% | 78.84% |
LLY leads on 2 of 2 profitability factors.
Dividend
| ACAD | LLY | |
|---|---|---|
| Dividend Yield | — | 0.58% |
| Payout Ratio | — | 23.23 |
ACAD and LLY split the dividend factors evenly.
Risk & Sentiment
| ACAD | LLY | |
|---|---|---|
| Short Interest | 5.74% | 1.29% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: ACAD overview, ACAD financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.